[Hengrui Pharmaceutical: company and subsidiaries get Drug Clinical trial approval] May 31, Hengrui Pharmaceutical announced that the company received approval from the State Drug Administration to issue a "Drug Clinical trial approval notice" for SHR7280 dry suspension, and will carry out clinical trials in the near future. Guangdong Hengrui Pharmaceutical, a subsidiary of Guangdong Hengrui Medicine, has received the approval notice of Drug Clinical trial for SHR-1905 injection approved by the State Drug Administration and will carry out clinical trials in the near future.